|
Abstract:
|
Drug combination therapy has been widely studied in oncology and other complex disease areas for the potential to improve treatment response, minimize development of resistance and/or adverse events. In the past decade, owing to the great success of immunotherapy revolutionizing the treatment of many deadly cancers for many cancer patients, combination therapy become even more important. Statisticians are also making progress on study design and trial analysis for combination therapy. this talk will share cross industry experience in this field based on the work from ASA oncology working group on trial design and analysis of combination therapy.
|
